1228076-27-4

Basic information

• Product Name: (4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine
• Synonyms: (4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine
• CAS NO: 1228076-27-4
• Molecular Weight: 332.334
• Mol File: 1228076-27-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: (4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine(1228076-27-4)
• EPA Substance Registry System: (4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine(1228076-27-4)

Safety Data

• Hazardous Substances Data: 1228076-27-4(Hazardous Substances Data)

Usage

General Description

(4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine is a chemical compound that consists of a fluorobenzyl group attached to a pyridinylamine group through a morpholinyl linker. The fluorobenzyl group is known for its use in organic synthesis and pharmaceutical research, while the nitropyridinylamine group has potential applications in the development of pharmaceuticals and agrochemicals. The morpholinyl linker provides flexibility and may contribute to the compound's solubility and bioavailability. (4-fluorobenzyl)(6-(morpholin-4-yl)-5-nitropyridin-2-yl)amine may have utility as a building block or intermediate in the synthesis of new chemical entities for various applications in the fields of medicine, agriculture, and material science. Its precise properties and potential uses would depend on further research and development.

Upstream product

• 1094323-33-7 4-(6-chloro-3-nitropyridin-2-yl)morpholine 
• 140-75-0 para-fluorobenzylamine 

Downstream Products

• 1228076-29-6 N-2-(4-fluorobenzyl)-6-morpholin-4-yl-pyridine-2,5-diamine 
• 1228076-12-7 2-(3,5-difluorophenyl)-N-[6-(4-fluorobenzylamino)-2-(morpholin-4-yl)pyridin-3-yl]acetamide 

Relevant articles and documents

Flupirtine and retigabine as templates for ligand-based drug design of KV7.2/3 activators

Drug induced liver injury (DILI) and tissue discoloration led to the recent discontinuation of the therapeutic use of the closely related drugs flupirtine and retigabine, respectively. Experience gained with these drugs strongly suggests that heterotetramer, voltage-gated potassium channels 2 and 3 (KV7.2/3) are valid targets for effective treatment of pain and epilepsy. Because the adverse effects are not related to the mechanism of action, it appears promising to investigate chemical modifications of these clinically validated, drug-like leads. In the present retro-metabolic drug design study, a series of 43 compounds were synthesized and characterized with regard to KV7.2/3 opening activity and efficacy. The most active compound 22d displays excellent potency (EC50 = 4 nM) and efficacy (154%) as a KV7.2/3 opener. Limited aqueous solubility hampered toxicity testing at concentrations higher than 63 μM, but this concentration was nontoxic to two hepatocellular cell lines (HEP-G2 and TAMH) in culture. The slightly less active but more soluble compound 25b (EC50 = 11 nM, efficacy 111%) showed an improved toxicity/activity ratio compared to flupirtine by three orders of magnitude and represents an attractive lead structure for the development of safer analgesics and antiepileptics.

NOVEL 2-MORPHOLINO-3-AMIDO-PYRIDINE DERIVATIVES AND THEIR MEDICAL USE

The present application discloses novel 2-morpholino-3-amido-pyhcline derivatives and their use as modulators of the voltage gated KV7 (KCNQ) potassium ion channels in the treatment of pain, neurodegenerative disorders, urinary incontinence, etc... In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.